MX2023009835A - Mutacion estabilizante de trimero de proteina de envoltura del vih. - Google Patents

Mutacion estabilizante de trimero de proteina de envoltura del vih.

Info

Publication number
MX2023009835A
MX2023009835A MX2023009835A MX2023009835A MX2023009835A MX 2023009835 A MX2023009835 A MX 2023009835A MX 2023009835 A MX2023009835 A MX 2023009835A MX 2023009835 A MX2023009835 A MX 2023009835A MX 2023009835 A MX2023009835 A MX 2023009835A
Authority
MX
Mexico
Prior art keywords
hiv envelope
envelope proteins
envelope protein
hiv
trimer
Prior art date
Application number
MX2023009835A
Other languages
English (en)
Inventor
Jaroslaw Juraszek
Johannes Petrus Maria Langedijk
Lucy Rutten
Original Assignee
Janssen Vaccines & Prevention Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Vaccines & Prevention Bv filed Critical Janssen Vaccines & Prevention Bv
Publication of MX2023009835A publication Critical patent/MX2023009835A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus human T-cell leukaemia-lymphoma virus
    • C07K14/155—Lentiviridae, e.g. human immunodeficiency virus [HIV], visna-maedi virus or equine infectious anaemia virus
    • C07K14/16—HIV-1 ; HIV-2
    • C07K14/162—HIV-1 ; HIV-2 env, e.g. gp160, gp110/120, gp41, V3, peptid T, CD4-Binding site
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • AIDS & HIV (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Se proporcionan proteínas de envoltura del virus de la inmunodeficiencia humana (VIH) que tienen mutaciones especificadas que estabilizan la forma trimérica de la proteína de envoltura. Las proteínas de envoltura del VIH descritas en la presente descripción tienen un porcentaje mejorado de formación de trímeros y/o un rendimiento de trímeros mejorado. También se proporcionan partículas que muestran proteínas de envoltura del VIH, moléculas de ácido nucleico y vectores que codifican las proteínas de envoltura del VIH, así como composiciones que contienen proteínas de envoltura del VIH, partículas, ácido nucleico, o vectores.
MX2023009835A 2021-02-23 2022-02-22 Mutacion estabilizante de trimero de proteina de envoltura del vih. MX2023009835A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP21158800 2021-02-23
PCT/EP2022/054336 WO2022180007A1 (en) 2021-02-23 2022-02-22 Trimer stabilizing hiv envelope protein mutation

Publications (1)

Publication Number Publication Date
MX2023009835A true MX2023009835A (es) 2023-09-04

Family

ID=74732664

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023009835A MX2023009835A (es) 2021-02-23 2022-02-22 Mutacion estabilizante de trimero de proteina de envoltura del vih.

Country Status (11)

Country Link
US (1) US20220265813A1 (es)
EP (1) EP4297778A1 (es)
JP (1) JP2024509769A (es)
KR (1) KR20230150269A (es)
CN (1) CN116867517A (es)
AR (1) AR124937A1 (es)
AU (1) AU2022224967A1 (es)
CA (1) CA3211197A1 (es)
MX (1) MX2023009835A (es)
TW (1) TW202302622A (es)
WO (1) WO2022180007A1 (es)

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5786464C1 (en) 1994-09-19 2012-04-24 Gen Hospital Corp Overexpression of mammalian and viral proteins
WO2004103312A2 (en) * 2003-05-19 2004-12-02 Progenics Pharmaceuticals, Inc. Peptides useful as hiv fusion inhibitors
US20100143302A1 (en) 2006-03-16 2010-06-10 Crucell Holland B.V. Recombinant Adenoviruses Based on Serotype 26 and 48, and Use Thereof
LT2358757T (lt) 2008-11-18 2018-11-26 Beth Israel Deaconess Medical Center Pagerinto ląstelinio imunogeniškumo priešvirusinės vakcinos
EP2451475A2 (en) 2009-07-06 2012-05-16 Novartis AG Self replicating rna molecules and uses thereof
CN102711794B (zh) 2010-01-04 2015-11-25 Kj生物科学有限公司 用于疫苗和诊断学的Dps融合蛋白
GB201108879D0 (en) 2011-05-25 2011-07-06 Isis Innovation Vector
CA2891349C (en) 2012-11-16 2023-07-18 Beth Israel Deaconess Medical Center, Inc. Recombinant adenoviruses and use thereof
WO2014124301A1 (en) 2013-02-07 2014-08-14 University Of Washington Through Its Center For Commercialization Self-assembling protein nanostructures
WO2016037154A1 (en) * 2014-09-04 2016-03-10 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Recombinant hiv-1 envelope proteins and their use
US9630994B2 (en) 2014-11-03 2017-04-25 University Of Washington Polypeptides for use in self-assembling protein nanostructures
HUE045993T2 (hu) 2015-12-15 2020-01-28 Janssen Vaccines & Prevention Bv Emberi immunhiány vírus antigének, vektorok, készítmények és alkalmazásukra szolgáló eljárások
SG10202001956UA (en) 2016-09-15 2020-04-29 Janssen Vaccines & Prevention Bv Trimer stabilizing hiv envelope protein mutations
GB201708444D0 (en) 2017-05-26 2017-07-12 Univ Oxford Innovation Ltd Compositions and methods for inducing an immune response
CA3069052A1 (en) 2017-07-19 2019-01-24 Janssen Vaccines & Prevention B.V. Trimer stabilizing hiv envelope protein mutations
SG11202000019RA (en) 2017-07-28 2020-02-27 Janssen Vaccines & Prevention Bv Methods and compositions for heterologous reprna immunizations
WO2019079337A1 (en) * 2017-10-16 2019-04-25 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services RECOMBINANT HIV-1 ENVELOPE PROTEINS AND THEIR USE
EA202091074A1 (ru) 2017-10-31 2020-07-22 Янссен Вэксинс Энд Превеншн Б.В. Аденовирус и его применения
KR20200074987A (ko) 2017-10-31 2020-06-25 얀센 백신스 앤드 프리벤션 비.브이. 아데노바이러스 및 이의 용도

Also Published As

Publication number Publication date
TW202302622A (zh) 2023-01-16
US20220265813A1 (en) 2022-08-25
AU2022224967A9 (en) 2024-05-16
AR124937A1 (es) 2023-05-24
KR20230150269A (ko) 2023-10-30
JP2024509769A (ja) 2024-03-05
CA3211197A1 (en) 2022-09-01
AU2022224967A1 (en) 2023-07-27
EP4297778A1 (en) 2024-01-03
CN116867517A (zh) 2023-10-10
WO2022180007A1 (en) 2022-09-01

Similar Documents

Publication Publication Date Title
PH12019500280A1 (en) Trimer stabilizing hiv envelope protein mutations
PH12020500025A1 (en) Trimer stabilizing hiv envelope protein mutations
CL2021002741A1 (es) Una proteína crispr de prevotella y francisella 1 (cpf1) aislada de lachnospiraceae bacterium nd2006; proteína de fusión que la comprende; ácido nucleico; vector; métodos para alterar el genoma de una célula o una molécula de adn bicatenario in vitro que utilizan dichas proteínas (divisional de sol. 201903004)
AU2017248121A1 (en) T cell receptors
AU2017248122A1 (en) T cell receptors
MX2019004499A (es) Sistemas de replicón de virus recombinante y usos de estos.
EP4389898A3 (en) T cell receptors
MX2020009514A (es) Anticuerpos anti-claudina 18.2 (cldn18.2).
EP4249064A3 (en) Novel fusion protein specific for cd137 and pd-l1
MX2022002747A (es) Proteinas de fusion de ca2-il15 para regulacion ajustable.
MX2021010039A (es) Novedosas proteinas de fusion especificas para cd137 y gpc3.
EP3235828A1 (en) Stable pseudotyped lentiviral particles and uses thereof
MX2019014397A (es) Polipeptidos que enlazan adamts5, mmp13 y agrecano.
MX2023012722A (es) Capsides de aav y usos de las mismas.
CR20230015A (es) Fusiones heterodiméricas de relaxina y usos de las mismas
MX2023007319A (es) Vacunas de acido nucleico.
MX2023009835A (es) Mutacion estabilizante de trimero de proteina de envoltura del vih.
EA202090326A1 (ru) Стабилизирующие тример мутации белка оболочки hiv
WO2020152318A3 (en) High growth influenza virus
MX2023009738A (es) Antigenos de rsv fb prefusion estabilizados.
EBASHI A new simple method of preparing actin from chicken gizzard
EP1570051A4 (en) HYBRID GENES AND COMPOSITIONS COMPRISING RRE AND CTE AND USES THEREOF
MX2023015400A (es) Variantes de interleucina 15.
MX2023001083A (es) Construcciones anti grupo de diferenciacion 93 (cd93) y usos de las mismas.
WO2024167830A3 (en) ANTI-SIRPα ANTIBODIES AND USES THEREOF